Rating: HOLD
| Metric | Value |
|---|---|
| Current Price | $756 |
| Triangulated Fair Value | $741 |
| 12-mo Scenario PWEV | $753 |
| Implied Return | -2% |
| Forward P/E | 17.1x |
| Market Cap | $88B |
| 52-Week Range | $634 – $998 |
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.
Investment Thesis
The bull case — 'Bull — Re-Rate' (8% weight) — targets $1,176, +56% vs spot. It needs Gross Margin to surprise to the upside.
The dashboard below is the whole argument on one page: spot ($756) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The structural case — 'Structural — Channel Disintermediation / Reimbursement' (20%) — targets $383, -49% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.
Key Debate
Gross Margin explains 82% of Monte Carlo outcome variance — the single variable that decides which side is right.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q2): management +0.56 vs analyst floor +0.38 → delta +0.18 (n=21 mgmt / 13 Q&A; 10th pctile across the S&P book, z -1.3).
Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q2 | +0.56 | +0.38 | +0.18 |
| 2026Q1 | +0.48 | +0.35 | +0.12 |
| 2025Q4 | +0.34 | +0.04 | +0.30 |
| 2025Q3 | +0.33 | +0.27 | +0.07 |
News (last 365d, 1000 articles): avg ticker sentiment +0.23 (bullish 30% / bearish 2%)
Scenario Analysis
The tree runs from a structural 'Structural — Channel Disintermediation / Reimbursement' downside ($383) to a 'Bull — Re-Rate' bull case ($1,176); the probability-weighted blend (PWEV $753) is -0% versus spot.
| Scenario | Probability | Target | Return |
|---|---|---|---|
| Structural — Channel Disintermediation / Reimbursement | 20% | $383 | -49% |
| Volume / Generic-Deflation Pressure | 17% | $619 | -18% |
| Base — Drug-Volume + Specialty Growth | 35% | $792 | +5% |
| Growth — Specialty / Services Expansion | 20% | $1,000 | +32% |
| Bull — Re-Rate | 8% | $1,176 | +56% |
| Probability-Weighted (PWEV) | — | $753 | -0% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Channel Disintermediation / Reimbursement (20%, $383). Structural impairment — channel disintermediation / reimbursement: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 382.88; probability: 0.2.
- Volume / Generic-Deflation Pressure (17%, $619). Cyclical downturn — pharmaceutical distribution volumes + specialty/biosimilar mix + generic deflation weakens for 1–2 years before normalising. Drivers — implied_target: 619.3; probability: 0.17.
- Base — Drug-Volume + Specialty Growth (35%, $792). Mid-cycle — normalised pharmaceutical distribution volumes + specialty/biosimilar mix + generic deflation; disciplined capital allocation; steady returns. Drivers — implied_target: 791.94; probability: 0.35.
- Growth — Specialty / Services Expansion (20%, $1,000). Upside — specialty + services expansion lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 999.91; probability: 0.2.
- Bull — Re-Rate (8%, $1,176). Upside tail — sustained tight conditions or a structural re-rate on specialty + services expansion. Drivers — implied_target: 1176.03; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $659 | -13% |
| Peer P/E re-rate | multiple | $693 | -8% |
| Peer EV/Revenue re-rate | multiple | $784 | +4% |
| Scenario PWEV | multiple | $753 | -0% |
| DCF (5-year + terminal) | cash flow + terminal × | $782 | +3% |
| Triangulated (weighted) | — | $741 | -2% |
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $659 and 42% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (82% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 8.0%, 14x terminal FCF multiple → $782. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 15.65x) implies $693. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.
Across all anchors the spread is tight (the methods corroborate one another).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|
| Drug Distribution | $403.4B | 100% | 5% | 2% | 17x | 1% | ESTIMATE |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | pharmaceutical distribution volumes + specialty/biosimilar mix + generic deflation |
| net_debt_or_cash_b | -4.64 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.01 |
| div_yield | 0.0041 |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | channel disintermediation / reimbursement |
| upside | specialty + services expansion |
Industry Context — Health Services
This name sits in the Health Services as a distributors. pharmaceutical distribution volumes + specialty/biosimilar mix + generic deflation Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: MCK (distributors) · COR (distributors) · CAH (distributors) · DGX (diagnostics) · LH (diagnostics) · HSIC (distributors)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Reimbursement / Disintermediation Pressure | 37% | 37% | |
| Mid-Cycle — Volume + Specialty Growth | 35% | 35% | |
| Upside — Specialty / M&A Re-Rate | 28% | 28% |
On the cluster's key downside — Reimbursement / Disintermediation Pressure () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The health_services cycle is the shared macro driver. Driver — drug/lab volumes + reimbursement + thin-margin distribution & specialty mix Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $424B | $8B | $4B | $4B | $7B | $6B |
| FY+2 | $445B | $9B | $4B | $4B | $7B | $6B |
| FY+3 | $463B | $9B | $5B | $4B | $7B | $5B |
| FY+4 | $481B | $10B | $5B | $4B | $7B | $5B |
| FY+5 | $496B | $10B | $5B | $5B | $7B | $5B |
| Terminal | — | — | — | — | $7B × 14x | $69B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 1% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 8.0% · Σ PV(FCF) $27B + PV(terminal) $69B = EV $96B; + net cash → equity $91B ÷ diluted shares 0.12B = $782/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $977/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 5% vs WACC 8% → below WACC — the incremental build is value-dilutive.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| COR | 0.2x | 14.24x | 5% | 2% |
| CAH | 0.239x | 19.76x | 5% | 1% |
| HSIC | 0.982x | 15.65x | 5% | 6% |
| Median | 0.239x | 15.65x | — | — |
Peer-median fwd P/E → $693; EV/Rev → $784.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $782 | 41% | $322 |
| Scenario PWEV | $753 | 29% | $222 |
| Monte Carlo median | $659 | 18% | $116 |
| Peer P/E | $693 | 12% | $82 |
| Triangulated | — | 100% | $741 |
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 9.8x | 11.9x | 14.0x | 16.1x | 18.2x |
|---|---|---|---|---|---|
| 6% | $659 | $756 | $853 | $950 | $1,047 |
| 7% | $631 | $724 | $816 | $909 | $1,001 |
| 8% | $605 | $694 | $782 | $870 | $959 |
| 9% | $581 | $665 | $749 | $834 | $918 |
| 10% | $557 | $638 | $718 | $799 | $880 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $-427 | $142 | $710 | $1,279 | $1,848 |
| -1.5pp | $-468 | $139 | $745 | $1,352 | $1,959 |
| +0.0pp | $-512 | $135 | $782 | $1,429 | $2,076 |
| +1.5pp | $-558 | $131 | $820 | $1,509 | $2,199 |
| +3.0pp | $-607 | $127 | $860 | $1,594 | $2,328 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Op margin ±3pp | $-512 | $2,076 | $2,588 |
| Terminal × ±15% | $694 | $870 | $177 |
| Revenue CAGR ±3pp | $710 | $860 | $150 |
| WACC ±1pp | $749 | $816 | $67 |
| FCF conversion ±10% | $782 | $782 | $0 |
Company lever — SoP/share vs Drug Distribution multiple (AI re-rating) (base 17x)
| Multiple | 11.9x | 14.4x | 17.0x | 19.5x | 22.1x |
|---|---|---|---|---|---|
| SoP/share | $40,990 | $49,610 | $58,574 | $67,194 | $76,158 |
Load-Bearing Assumptions
DCF: WACC 8%, terminal multiple 14×, FY+5 revenue $496B. Triangulation leans 41% on DCF, 29% on PWEV.
Reasons the Thesis Could Fail (Falsifiable)
A miss on Gross Margin drops the case toward the structural target $383.
Fact / Inference / Speculation
- FACT: Spot $756; 52-week range $634–$998; engine rating HOLD; base-case target $753 (-0%).
- INFERENCE: Triangulated FV $741 (-2%). Gross Margin explains 82% of Monte Carlo outcome variance — the single variable that decides which side is right.
- SPECULATION: At current prices the embedded bet is that Gross Margin surprises to the upside — Gross Margin carries 82% of outcome variance.
Recommendation: HOLD
Balanced: triangulated fair value $741 (-2% vs spot); the outcome hinges on Gross Margin. The debate is Gross Margin (82% of variance) — a fundamental call. SBC runs —M TTM (disclosed in the appendix).